Nov 012022
Drug Name |
Active Ingredient(s) |
Approval Date |
FDA-Approved Use on Approval Date |
Press Release |
Drug Trials Snapshot |
| Tecvayli | teclistamab-cqyv | 10/25/2022 | To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapy | Drug Trials Snapshot | |
| Imjudo | tremelimumab | 10/21/2022 | To treat unresectable hepatocellular carcinoma | Drug Trials Snapshot |
Sorry, the comment form is closed at this time.